Nat Rev Endocrinol. 2009 May;5(5):262-9.

Incretin-based therapies for type 2 diabetes mellitus.

Source

Department of Medicine, Samuel Lunenfeld Research Institute, Mt Sinai Hospital, University of Toronto, Toronto M5T 3L9, Canada.

Abstract

Incretin-based drugs, such as glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase 4 inhibitors, are now routinely used to treat type 2 diabetes mellitus. These agents regulate glucose metabolism through multiple mechanisms, their use is associated with low rates of hypoglycemia, and they either do not affect body weight (dipeptidyl peptidase 4 inhibitors), or promote weight loss (glucagon-like peptide-1 receptor agonists). The success of exenatide and sitagliptin, the first therapies in their respective drug classes to be based on incretins, has fostered the development of multiple new agents that are currently in late stages of clinical development or awaiting approval. This Review highlights our current understanding of the mechanisms of action of incretin-based drugs, with an emphasis on the emerging clinical profile of new agents.

PMID:: 19444259; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Diabetes Type 2 - MedlinePlus Health Information

Libraries

LinkOut Holdings

Supplemental Content

Save items

Related citations in PubMed

Review Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. [Pharmacotherapy. 2010]
Review Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.
Drab SR. Pharmacotherapy. 2010 Jun; 30(6):609-24.
Review Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. [Ann Pharmacother. 2011]
Review Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR, Hurren KM. Ann Pharmacother. 2011 Jul; 45(7-8):850-60. Epub 2011 Jul 5.
Review Efficacy and safety of incretin based therapies: clinical trial data. [J Am Pharm Assoc (2003). 2009]
Review Efficacy and safety of incretin based therapies: clinical trial data.
White J. J Am Pharm Assoc (2003). 2009 Sep-Oct; 49 Suppl 1:S30-40.
Review Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. [Expert Opin Investig Drugs. 2008]
Review Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Mikhail N. Expert Opin Investig Drugs. 2008 Jun; 17(6):845-53.
Review Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting. [Am J Manag Care. 2010]
Review Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
Garber AJ. Am J Manag Care. 2010 Aug; 16(7 Suppl):S187-94.

See reviews... See all...

Cited by 25 PubMed Central articles

Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates. [Proc Natl Acad Sci U S A. 2012]
Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates.
Santi DV, Schneider EL, Reid R, Robinson L, Ashley GW. Proc Natl Acad Sci U S A. 2012 Apr 17; 109(16):6211-6. Epub 2012 Apr 2.
Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. [PLoS One. 2012]
Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis.
Li Y, Chigurupati S, Holloway HW, Mughal M, Tweedie D, Bruestle DA, Mattson MP, Wang Y, Harvey BK, Ray B, et al. PLoS One. 2012; 7(2):e32008. Epub 2012 Feb 23.
Discovery of dual-action membrane-anchored modulators of incretin receptors. [PLoS One. 2011]
Discovery of dual-action membrane-anchored modulators of incretin receptors.
Fortin JP, Chinnapen D, Beinborn M, Lencer W, Kopin AS. PLoS One. 2011; 6(9):e24693. Epub 2011 Sep 14.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Incretin-based therapies for type 2 diabetes mellitus.
Incretin-based therapies for type 2 diabetes mellitus.
Nat Rev Endocrinol. 2009 May ;5(5):262-9.

PubMed
In vivo and in vitro derived Palo Alto lines of Plasmodium falciparum are geneti...
In vivo and in vitro derived Palo Alto lines of Plasmodium falciparum are genetically unrelated.
Mol Biochem Parasitol. 1991 Aug ;47(2):167-78.

PubMed
Diversity and complexity in DNA recognition by transcription factors.
Diversity and complexity in DNA recognition by transcription factors.
Science. 2009 Jun 26 ;324(5935):1720-3. Epub 2009 May 14 .

PubMed
Mechanisms of spontaneous mutation in DNA repair-proficient Escherichia coli.
Mechanisms of spontaneous mutation in DNA repair-proficient Escherichia coli.
Mutat Res. 1991 Sep-Oct ;250(1-2):55-71.

PubMed
Global priorities for patient safety research.
Global priorities for patient safety research.
BMJ. 2009 May 14 ;338:b1775. doi: 10.1136/bmj.b1775.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: